Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.Clinical pharmacokinetics · 2014
   Trial
2. Severe Presentation of De Novo Type II Diabetes in Abiraterone and Prednisone Therapy.Cureus · 2025
   Article
3. Making the Case for Autophagy Inhibition as a Therapeutic Strategy in Combination with Androgen-Targeted Therapies in Prostate Cancer.Cancers · 2023
   Review
4. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.Molecules (Basel, Switzerland) · 2022
   Review
5. Morusflavone, a New Therapeutic Candidate for Prostate Cancer by CYP17A1 Inhibition: Exhibited by Molecular Docking and Dynamics Simulation.Plants (Basel, Switzerland) · 2021
   Article
6. Abiraterone suppresses irradiated lung cancer cells-induced angiogenic capacities of endothelial cells.Journal of bioenergetics and biomembranes · 2021
   Article
7. Hyperpolarisation of weakly binding N-heterocycles using signal amplification by reversible exchange.Chemical science · 2021
   Article
8. CYP17A1 and Androgen-Receptor Expression in Prostate Carcinoma Tissues and Cancer Cell Lines.Current urology · 2019
   Article
9. Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats.Hormones & cancer · 2018
   Article
10. Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay.Archives of toxicology · 2017
    Article
11. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.The Prostate · 2016
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.